StockNews.com initiated coverage on shares of Titan Pharmaceuticals (NASDAQ:TTNP – Free Report) in a research note published on Monday morning. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Titan Pharmaceuticals Price Performance
NASDAQ:TTNP opened at $7.10 on Monday. The firm’s 50-day moving average price is $7.34 and its 200-day moving average price is $7.23. The company has a market capitalization of $6.46 million, a PE ratio of -0.87 and a beta of 1.33. Titan Pharmaceuticals has a 1-year low of $5.00 and a 1-year high of $16.60.
Institutional Trading of Titan Pharmaceuticals
A number of institutional investors have recently made changes to their positions in the stock. State Street Corp purchased a new stake in shares of Titan Pharmaceuticals during the 3rd quarter valued at about $41,000. Millennium Management LLC boosted its holdings in shares of Titan Pharmaceuticals by 516.8% during the 2nd quarter. Millennium Management LLC now owns 63,106 shares of the specialty pharmaceutical company’s stock valued at $35,000 after acquiring an additional 52,874 shares during the last quarter. Virtu Financial LLC purchased a new stake in shares of Titan Pharmaceuticals during the 2nd quarter valued at about $35,000. Finally, Renaissance Technologies LLC boosted its holdings in shares of Titan Pharmaceuticals by 559.3% during the 2nd quarter. Renaissance Technologies LLC now owns 240,710 shares of the specialty pharmaceutical company’s stock valued at $135,000 after acquiring an additional 204,200 shares during the last quarter. Hedge funds and other institutional investors own 31.49% of the company’s stock.
Titan Pharmaceuticals Company Profile
Titan Pharmaceuticals, Inc, a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union.
Read More
- Five stocks we like better than Titan Pharmaceuticals
- How to Calculate Options Profits
- United Airlines Soars on Earnings Beat
- 5 Top Rated Dividend Stocks to Consider
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Energy and Oil Stocks Explained
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Titan Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Titan Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.